Posted on 04/29/2020 12:25:32 PM PDT by SeekAndFind
BALTIMORE, MD -- Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing the effectiveness of hydroxychloroquine as a therapy to prevent infection and symptoms in individuals who have been exposed to COVID-19-positive individuals. The trial is significant because it focuses on preventing COVID-19 and does not involve individuals who are ill with infection but rather healthy individuals who have been exposed.
The research is part of a national study being conducted across the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation (BMGF), Wellcome, and Mastercard, with funding from an array of public and philanthropic donors, to speed up the response to the COVID-19 pandemic by funding the identification, assessment, development and scale up of treatments.
Principal investigators for the COVID-19 Post-Exposure Prophylaxis (PEP) trial - which is being conducted remotely among volunteers throughout the Baltimore-Washington area - are Kathleen Neuzil, MD, MPH, the Myron M. Levine, MD, DTPH, Professor in Vaccinology, Professor of Medicine and Pediatrics, Director of the Center for Vaccine Development and Global Health (CVD), and Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director of the CVD's Malaria Research Program.
Both Dr. Neuzil and Dr. Laufer are infectious disease specialists, with extensive experience in vaccine and infectious disease research. Dr. Laufer, is a hydroxychloroquine expert, having spent years researching the therapy's effectiveness in children, pregnant women and people living with HIV, as well as the epidemiology of drug-resistant malaria.
"We know that many COVID-19-positive individuals have mild or no symptoms but are still very contagious. If we can prevent infection or symptoms in individuals who have been exposed to them, we can significantly alter the course of this pandemic," said Dr. Neuzil.
"Our goal is to reach adult family and household members who live with someone who has recently been diagnosed with COVID-19," said Dr. Laufer. "To be able to really see how to best protect these exposed individuals, we need to enroll as many people as we can into this study. We want to work with testing sites, public health facilities, medical practices, long-term care facilities and hospitals to identify anyone who might be eligible. Most COVID-19 infection is transmitted within households, so we are working to protect the health of the individuals in the family and limit the broader spread of COVID-19 infection. This could serve as a critical preventative treatment."
The research is critical as more than three quarters of COVID-19 transmissions occur through close contact within households. The study is being conducted remotely through online video calls and by answering questions via email. Individuals who qualify for the randomized study will take either hydroxychloroquine or a placebo daily for 14 days. Volunteers who participate in the study will be asked to take the medication, complete an online survey to assess their symptoms, and collect a sample by swabbing the inside of their nose every day for 14 days. On Day 28 a final swab will be collected and a survey completed.
"This research at the University of Maryland School of Medicine is critically important in understanding how we can prevent serious illness from COVID-19. Importantly, a preventative therapy would protect first responders and frontline workers in health facilities and elsewhere. If we can prevent COVID-19 infection, we can help reduce infection and mortality among our most vulnerable individuals," said Dean E. Albert Reece, MD, PhD, MBA, who is also Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor, University of Maryland School of Medicine.
This research is part of a larger national study led by the University of Washington. This study is a randomized, multi-center study, enrolling nationwide up to 2,000 men and women who meet the eligibility criteria. For more information visit http://www.covid19pepstudy.org.
"Our goal is to stop transmission of COVID-19 in the community," said the multi-site study's principal investigator Ruanne Barnabas, MBChB, DPhil, Associate Professor of Global Health, University of Washington, "We currently don't know if hydroxychloroquine works, but through this study we will learn in as short a timeframe as possible whether hydroxychloroquine can prevent transmission in people exposed to the virus."
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of Medicine and Medical System ("University of Maryland Medicine") has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu.
About the Center for Vaccine Development and Global Health
For over 40 years, researchers in the Center for Vaccine Development and Global Health have worked domestically and internationally to develop, test, and deploy vaccines to aid the world's underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has worked to eliminate vaccine-preventable diseases. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, malaria and other infectious diseases. CVD's research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. CVD researchers are developing new and improved ways to diagnose, prevent, treat, control, and eliminate diseases of global impact. Currently, these diseases include typhoid, Shigella, E. coli diarrhea, malaria, and other vaccine-preventable infectious diseases. CVD researchers have been involved in critical vaccine development for emerging pathogens such as Ebola and Zika. In addition, CVD's work focuses on the ever-growing challenge of antimicrobial resistance.
Later
and they deliberately leave out the Zinc and the antibiotic to sabotage it. Scum.
“The trial is significant because it focuses on preventing COVID-19 and does not involve individuals who are ill with infection but rather healthy individuals who have been exposed”
Where’s the Zinc? And why testing only as a prophylaxis and not an early treatment to hasten recovery as has been claimed by so many Drs?
“We know that many COVID-19-positive individuals have mild or no symptoms but are still very contagious. If we can prevent infection or symptoms in individuals who have been exposed to them, we can significantly alter the course of this pandemic,” said Dr. Neuzil.
not really. i know of a hospital system case where out of several thousand health workers tested reliably for covid, where less than 10 “asymptomatic” people tested positive. and even those may develop symptoms later. note, these are people with lots of potential covid contacts.
based this fact, the “large numbers” of asymptomatic spreaders is just another myth.
The progtards can’t bury it any longer.
BTW, almost all MOVs contain Zinc.
A ZPak or Doxy only needed after infectious process starts. This study uses HCQ as a prophy.
Which guarantees that it won't work because Gates wants VACCINE, not preventative/therapeutic.
thanks
What is an “MOV?”
It is late in the day.
One of the best kept secrets around is BHT short for butylated hydroxy toluene.
It has been around for the better part of thirty years, has been approved as a food additive by the FDA as safe for human consumption in small quantities and using common sense. Without going into all the details which would fill many pages some of the benefits are difficult to ignore even so pharmaceutical as well as the medical profession does their best to do so.
Some of the reasons are that that there is no money to be made by pharmaceutical companies as patents related to BHT ran out long time ago and in order to have it approved for medical application it would require an immeasurable amounts of human tests with expenditures in the millions of Dollars which most likely will never be recovered.
On the other hand many doctors may know about it but will refrain from suggesting it as recommending anything which is not approved by the FDA would leave them wide open to lawsuits, as it is pretty well known that one of the American dreams is, to fall on your neighbors property and then sue them for what ever they can get.
Over the years enough information about BHT has surfaced that if used in small quantities to achieve a particular result, such as from 100 mg to about 1g (one gram or 1000mg) and in most cases 250mg to 450mg may do a nice job for some of the things suggested, it may be less harmful than an equivalent amount of Aspirins. Again do your own research and use common sense which appears to be in short supply these days.
Even so, if you still apprehensive or hesitant use it only when one of those nasty viruses appears on the scene and use it as a prophylactic in a small quantity perhaps 200 mg and once the danger subside stop taking it. The catch is that in order to do its job BHT works better before you get sick, as BHT will NOT REPAIR ANY DAMAGE which may already have been done by an infectious disease such as the corona virus. Even so if taken afterwards BHT will still continue to disable lipid covered viruses, but to repair any damage already caused may require different medications.
So why to take BHT on the firs place? It has been long known that BHT will remove the lipid layer or cover from LIPID COVERED viruses and the coronavirus happens to be just such a virus and by doing so will prevent such a virus from attaching itself and do its dirty work.
The Principal Benefits of BHT
In order of importance, supplementing with BHT can help with:
Reduce and prevent viral infections such as herpes, thus terminating their outbreaks. Also BHT is effective against many different human and animal viruses including CMV (cytomegalovirus),9 pseudorabies,10 genital herpes,11HIV,12 and some strains of influenza.13 A few of the viruses that have a lipid envelope and may be treated by BHT include herpes simplex I, herpes simplex II, herpes zoster, CMV, West Nile virus, HIV virus, influenza virus, hepatitis B and C viruses, avian flu influenza virus and the SARS virus. However, BHT has not been clinically tested to treat these infections.
The CORONAVIRUS is also a lipid covered virus and BHT affects the lipid covering and in turn prevents the virus from attaching itself and do its damage. Now keep in mind that very few things in life are perfect and this holds true for vaccines as well. So when everything comes down to being cut and dried, do you prefer risking being infected with a nasty virus with all kinds of unpredictable side effects or take a chance with some substance which overall has a very good safety record.
In addition to BHT, chances are better than good that it may mutate and by the time someone comes up with a vaccine, we have to start all over again. On the other hand BHT does not care if this virus mutates or not, as long as it has a lipid coating it will disable the virus by removing its lipid coating. And as far as safety is concerned it has a better record than either smoking or consuming alcohol.
>>”....the “large numbers” of asymptomatic spreaders is just another myth.”<<
I tend to agree, although I do believe that a large number of people have been infected and recovered without ever seeing a doctor, either because they were stubborn or because they didn’t ever get all that sick at the time.
Iceland got the “50% of all positive cases were asymptomatic” rumor going. It was based on the private company’s testing where they were testing people who were not at the hospital. As a result they were only finding a small number of positives per hundred tests, like one or two per hundred.
And, when they found them, half were asymptomatic, they said. Well, unless they followed up, they’d never know how many of that 50% later came down with symptoms, and I don’t think they followed up that way.
It was just what you’d expect when a disease has a week or so of no symptoms after catching it, and that works its way through in only a couple weeks if one doesn’t get a serious case of it. And since these people were not being tested at the hospital, it’s likely that the positive cases were not serious, at least at the time of testing.
But all it took was that one headline, based on misleading information, and forever after “50% of all Covid cases are asymptomatic.” Not True, or at least Not Proved.
the problem is that the so called “experts” about this disease have been the main “asymptomatic spreaders” of this propaganda pandemic, aided and abetted by the fake news media.
i just read the biased quote from a said impressively titled expert in this article (and all over similar posts on FR). i mean the doctor i quoted already has an unscientific and—i believe—demonstratively false bias baked into her world view. if she’s part of it, this study has little or no chance of giving us any useful information at all. what a criminal waste of resources, with the potential of leading our healthcare system and nation into error as a side-effect.
these “new researchers” in power don’t even talk like proven scientists, i refuse to sully the word “science” with anything they do.
MOV = Multiple Oral Vitamin
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.